Compare Kimberly Clark Corp (KMB) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Sanofi SA — how do they compare? Kimberly Clark Corp trades at $107.42 (market cap $36.01B), while Sanofi SA trades at $43.72 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 2.9× Kimberly Clark Corp's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| KMB | SNY | |
|---|---|---|
Market Cap | $36.01B | $104.83B |
Sector | Consumer Staples | Health |
52-Week High | $136.77 | $52.34 |
52-Week Low | $93.05 | $41.33 |
Enterprise Value | $42.55B | $121.32B |
Dividend Yield | 4.72% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $108.43, up 0.07% on the day, with a neutral technical signal and bullish moving averages. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.97 exceeding the $1.93 estimate. Revenue declined to $16.45B in 2025, but net income margin remains strong at 12.8%. Recent news highlights KMB's innovation strategy and its status as a Dividend King, with a 4.5% yield attracting income investors.
KMB offers stable income with a high dividend yield and solid fundamentals, but faces revenue pressure and competitive risks. Analyst consensus is a $115.33 price target with a hold-heavy rating. Key risks include consumer sentiment impacts and input cost inflation, while the pending Kenvue merger provides growth potential.
SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.
SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
